Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Brucella and Coxiella; if you don't look, you don't find

Jonathan R Lambourne and Tim Brooks
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.15-1-91
Clin Med February 2015
Jonathan R Lambourne
AHospital for Tropical Diseases, University College London Hospitals NHS Trust, London, UK
Roles: specialty trainee in infectious diseases and microbiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jonathan.lambourne@nhs.net
Tim Brooks
BPublic Health England, Salisbury, UK
Roles: consultant microbiologist and clinical services director of the Rare and Imported Pathogens Laboratory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

ABSTRACT

Brucella and Coxiella are similar; both are obligate intracellular, zoonotic pathogens with a broad geographic distribution. Infection in animals is usually asymptomatic, but causes fetal loss and therefore has significant economic impact. Human infection may be asymptomatic or give rise to either organ-specific or multi-system disease. Organism culture is challenging for Coxiella and can lack sensitivity for Brucella. Therefore, infection is most commonly diagnosed by serology, but this may be negative in early infection and serology results may be challenging to interpret. Both Brucella and Coxiella are typically susceptible to a wide range of antimicrobials, but long courses may be needed.

KEYWORDS 
  • Brucella
  • Coxiella
  • zoonosis
  • diagnosis
  • fever

Key points

  • Brucella and Coxiella are zoonoses with a wide geographic distribution

  • Human infection may be asymptomatic, organ-specific or multi-system

  • Serological tests may be negative in early infection

  • Long courses of antimicrobials may be required for effective treatment

Coxiella

Coxiella burnetii is the cause of Q fever, a term first used in 1983 during the investigation of a cluster of febrile Australian meat workers.1 Infection typically follows inhalation or ingestion of spores, which are able to survive in soil, dairy produce and water for many months. Direct animal contact is not required as spores may be carried long distances by the wind. Coxiella is endemic in most countries. In Southern Europe and North Africa it is the causative agent in up to 10% of patients admitted with a febrile illness,2 and seroprevalence rates of over 30% have been reported in some countries, including Holland.3,4

Asymptomatic or mild infection is probably the norm following inoculation. What determines whether initial exposure is followed by eradication or chronic carriage is as yet unknown. Acute infection presents following an incubation period of 2–5 weeks and often manifests as an undifferentiated febrile illness, a respiratory illness with cough and variable radiological findings,5 or as an aseptic meningitis, usually with a normal cerebrospinal fluid (CSF) white cell count but raised protein and is often accompanied by hepatitis.6 Chronic infection can result in endocarditis, hepatitis, osteomyelitis and central nervous system (CNS) infection. Coxiella endocarditis usually affects abnormal or prosthetic valves and is often complicated by arterial emboli and immune complex-mediated skin and renal disease. However fever may be absent.7 Reactivation of latent infection is associated with impaired cell-mediated immunity, including that associated with pregnancy.8

Coxiella cannot be cultured using routine lab methods. Serology is the mainstay of diagnosis,9,10 but may take 2–6 weeks to become positive, up to 60% of acutely infected patients have negative initial serology.11 Polymerase chain reaction (PCR) assays can rapidly and reliably diagnose acute Q fever prior to development of a detectable antibody response.12 During infection, C burnetii varies its lipopolysaccharide (LPS) coat, the primary antigenic target.13 Phase II LPS is produced first, switching to phase I LPS several weeks to months later.10 Acute Q is diagnosed by a positive PCR or by a four-fold increase in phase II IgG antibody titer between acute and convalescent paired sera, and is suggested by either phase II IgM ≥1:50 and/or phase II IgG ≥1:200.6,10 Chronic Q is diagnosed by phase I IgG ≥1:800 and suggested by phase I IgG ≥1:128 and <1:800.6 In chronic infection, IgM is typically negative but titres may remain elevated for 12 months.

Coxiella are typically susceptible to a range of antimicrobials including tetracyclines, rifampicin, chloramphenicol, fluroquinolones and macrolides. Hydroxychloroquine alkalinises phagolysosomes, in which Coxiella resides,13,14 and may help increase the bactericidal effect of some of these agents. The ideal agent(s) and duration vary with the disease manifestation; acute infection usually requires 2–3 weeks, whereas chronic infection may require many months of treatment, guided by clinical progress and lab investigations such as Coxiella titres, erythrocyte sedimentation rate (ESR) and haemoglobin.6 A transthoracic echocardiogram should be considered for all patients diagnosed with acute Q, as patients with valvular abnormalities are predisposed to chronic infection, and should undergo regular serological follow up.15

Brucella

In 1887, Dr David Bruce described the causal relationship between Brucella species and the disease ‘Malta fever’. Human infection occurs following inhalational or mucosal contact with animal blood and body fluids, or ingestion of infected unpasteurised milk, cheese and meat. Brucella may be viable for 48 hours in milk, weeks in frozen meat and 3 months in unpasteurised cheese.16 A number of Brucella species have been reported to cause human disease, including B melitensis, B abortus, B suis and B canis, with B melitensis and B suis associated with more severe disease. There is some species-reservoir specificity, for example, B melitensis affects mainly ungulates (goats, sheep and camels) whereas B abortus mainly infects horses and ruminants.17 Brucella is the most common bacterial zoonosis worldwide, with at least 500,000 new cases reported each year. Brucella infection causes disease worldwide, especially in Arabia, the Mediterranean, Latin America and Central Asia.17 It has been reported that, in Kuwait, Brucella infection accounts for 10% of acute medical admissions.18

Following inoculation, many individuals remain asymptomatic. Clinical disease may be acute (<1 month), subacute (1–6 months) or chronic (> 6 months) and may present with systemic upset or disease limited to a single organ system.18 Common acute manifestations include an undifferentiated febrile illnesses, meningitis, encephalitis, septic arthritis and epididymo-orchitis. Chronic manifestations include systemic upset alone and/or with localised infection such as spondylitis, uveitis and endocarditis. Brucella may cause an ‘undulant’ fever, typically occurring in the late afternoon, which may be associated with focal sweating, which may have a strong mouldy smell.

Brucella grows on standard lab media, but detection requires prolonged incubation due to the organisms’ slow doubling time. Culture sensitivity varies from 15% to 90% depending on disease stage, sample type and culture media used.19 Sensitivity is highest in early infection and when bone marrow samples are cultured. PCR has shown promise, but there are no standardised methods. Serology is the mainstay of diagnosis, and has a sensitivity ranging from 65% to 95%, depending on disease stage and technique(s) used. The Public Health England Brucella reference unit performs four assays on all samples; microscopic agglutination (MAG), complement fixation (CF), and IgG and IgM-specific ELISAs.20 Brucella infection is suggested by the following; MAG titre ≥1:160, CF titre >1:4 and/or enzyme-linked immunosorbent assay (ELISA) titre ≥1:20. Comparing IgG and IgM titres can help differentiate acute from chronic infection, although elevated IgM titres are present for 12 months in 50% of cases.

Brucella species are typically susceptible to a range of antibiotics, including tetracyclines, rifampicin, aminoglycosides, ceftriaxone and cotrimoxazole. Its intracellular sanctuary site and slow doubling time warrants courses of at least six weeks. Longer treatment and/or combination therapy may be used for more ‘complicated’ infections, such as spondylitis, neurobrucellosis, endocarditis.21 Relapse occurs in 5—15% of cases, typically due to inadequate adherence, dose or duration. Relapse due to antibiotic resistance is rare.

  • © 2015 Royal College of Physicians

References

  1. 1.↵
    1. Derrick EH
    . “Q” fever, a new fever entity: clinical features, diagnosis and laboratory investigation. Rev Infect Dis 1983;5:790–800.doi:10.1093/clinids/5.4.790
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Vanderburg S,
    2. Rubach MP,
    3. Halliday JE,
    4. Cleaveland S,
    5. Reddy EA,
    6. Crump JA
    . Epidemiology of Coxiella burnetii infection in Africa: a OneHealth systematic review. PLoS Negl Trop Dis 2014;8:e2787.doi:10.1371/journal.pntd.0002787
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Richardus JH,
    2. Donkers A,
    3. Dumas AM,
    4. et al
    . Q fever in the Netherlands: a sero-epidemiological survey among human population groups from 1968 to 1983. Epidemiol Infect 1987;98:211–9.doi:10.1017/S0950268800061938
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Mak DB,
    2. Fry DF,
    3. Bulsara MK
    . Prevalence of markers of Q fever exposure in the Kimberley Western Australia. Commun Dis Intell Q Rep 2003;27:267–71.
    OpenUrlPubMed
  5. 5.↵
    1. Marrie TJ.
    . Coxiella burnetii pneumonia. Eur Respir J 2003;21:713–9.doi:10.1183/09031936.03.00099703
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Anderson A,
    2. Bijlmer H,
    3. Fournier PE,
    4. et al
    . Diagnosis and management of Q fever – United States 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep 2013;62:1–30.
    OpenUrl
  7. 7.↵
    1. Marrie TJ,
    2. Raoult D
    . Q fever – a review and issues for the next -century. Int J Antimicrob Agents 1997;8:145–61.doi:10.1016/S0924-8579(96)00369-X
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Langley JM,
    2. Marrie TJ,
    3. Leblanc JC,
    4. Almudevar A,
    5. Resch L,
    6. Raoult D
    . Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. Am J Obstet Gynecol 2003;189:228–32.doi:10.1067/mob.2003.448
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Raoult D,
    2. Marrie T
    . Q fever. Clin Infect Dis 1995;20:489–95; quiz 96.doi:10.1093/clinids/20.3.489
    OpenUrlFREE Full Text
  10. 10.↵
    1. Fournier PE,
    2. Marrie TJ,
    3. Raoult D
    . Diagnosis of Q fever. J Clin Microbiol 1998;36:1823–34.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Fournier PE,
    2. Raoult D
    . Comparison of PCR and serology assays for early diagnosis of acute Q fever. J Clin Microbiol 2003;41:5094–8.doi:10.1128/JCM.41.11.5094-5098.2003
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Schneeberger PM,
    2. Hermans MH,
    3. van Hannen EJ,
    4. Schellekens JJ,
    5. Leenders AC,
    6. Wever PC
    . Real-time PCR with serum samples is indispensable for early diagnosis of acute Q fever. Clin Vaccine Immunol 2010;17:286–90.doi:10.1128/CVI.00454-09
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Voth DE,
    2. Heinzen RA
    . Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii. Cell Microbiol 2007;9:829–40.doi:10.1111/j.1462-5822.2007.00901.x
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Flannagan RS,
    2. Cosio G,
    3. Grinstein S
    . Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009;7:355–66.doi:10.1038/nrmicro2128
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Wielders CC,
    2. Morroy G,
    3. Wever PC,
    4. Coutinho RA,
    5. Schneeberger PM,
    6. van der Hoek W.
    . Strategies for early detection of chronic Q-fever: a systematic review. Eur J Clin Invest 2013;43:616–39.doi:10.1111/eci.12073
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Young EJ
    . Suvannoparrat U. Brucellosis outbreak attributed to ingestion of umpasteurized goat cheese. Arch Intern Med 1975;135:240–3.doi:10.1001/archinte.1975.00330020044005
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Franco MP,
    2. Mulder M,
    3. Gilman RH,
    4. Smits HL
    . Human brucellosis. Lancet Infect Dis 2007;7:775–86.doi:10.1016/S1473-3099(07)70286-4
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lulu AR,
    2. Araj GF,
    3. Khateeb MI,
    4. Mustafa MY,
    5. Yusuf AR,
    6. Fenech FF
    . Human brucellosis in Kuwait: a prospective study of 400 cases. Q J Med 1988;66:39–54.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Memish Z,
    2. Mah MW,
    3. Al Mahmoud S,
    4. Al Shaalan M,
    5. Khan MY
    . Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 2000;40:59–63.doi:10.1053/jinf.1999.0586
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Sharma R,
    2. Chisnall C,
    3. Cooke RP
    . Evaluation of in-house and commercial immunoassays for the sero-diagnosis of brucellosis in a non-endemic low prevalence population. J Infect 2008;56:108–13.doi:10.1016/j.jinf.2007.10.010
    OpenUrlCrossRefPubMed
  21. 21.↵
    . Corbel MJ, Elberg SS, Cosivi O. Brucellosis in humans and animals. Geneva: World Health Organization 2006.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Brucella and Coxiella; if you don't look, you don't find
Jonathan R Lambourne, Tim Brooks
Clinical Medicine Feb 2015, 15 (1) 91-92; DOI: 10.7861/clinmedicine.15-1-91

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Brucella and Coxiella; if you don't look, you don't find
Jonathan R Lambourne, Tim Brooks
Clinical Medicine Feb 2015, 15 (1) 91-92; DOI: 10.7861/clinmedicine.15-1-91
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Key points
    • Coxiella
    • Brucella
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Dengue: an update for clinicians working in non-endemic areas
  • Human African trypanosomiasis in non-endemic countries
Show more CME SECTION: Tropical medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians